Rubicon Research made a strong debut on Dalal Street on Thursday, listing at a 28% premium over its issue price of ₹485 per share. The pharmaceutical company's ₹1,377.5 crore IPO, which drew an overwhelming 104 times subscription, opened at ₹620 on the NSE amid strong demand from institutional and retail investors alike.